Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks
CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The...
Pharma
Iterum’s Sulopenem receives FDA approval for treatment of uncomplicated urinary tract infections
Sulopenem was superior to amoxicillin/clavulanate and ciprofloxacin in treating antimicrobial resistant uncomplicated urinary tract infections. The antibiotic was safe and...
Astellas: Vyloy improves survival in patients with advanced gastric cancer
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher...
Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration
Patients with wet age-related macular degeneration receiving CLS-AX achieved stable visual acuity, and retinal thickness for up to six months....
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible...
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH)
ALG-055009, a thyroid hormone receptor agonist, significantly reduced liver fat in patients with MASH after 12 weeks of treatment. ALG-055009...
AstraZeneca’s FluMist first and only self-administered flu vaccine
FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by...
Bayer’s Kerendia demonstrates success in phase 3 clinical trials for treatment of heart failure
A phase 3 trial showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo. Hyperkalemia was greater...
AbbVie’s novel epkinly results in meaningful treatment response in patients with treatment-refractory lymphoma
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade...
Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of...